Lixte Biotechnology Holdings Inc (NASDAQ:LIXTW) — Market Cap & Net Worth
Market Cap & Net Worth: Lixte Biotechnology Holdings Inc (LIXTW)
Lixte Biotechnology Holdings Inc (NASDAQ:LIXTW) has a market capitalization of $212.85 ($212.85) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31858 globally and #6315 in its home market, demonstrating a -68.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lixte Biotechnology Holdings Inc's stock price $0.02 by its total outstanding shares 9675 (9.68K). Review Lixte Biotechnology Holdings Inc (LIXTW) financial obligations to assess the company's total debt and financial obligations.
Lixte Biotechnology Holdings Inc Market Cap History: 2020 to 2025
Lixte Biotechnology Holdings Inc's market capitalization history from 2020 to 2025. Data shows change from $8.71K to $212.85 (-51.19% CAGR).
Lixte Biotechnology Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lixte Biotechnology Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LIXTW by Market Capitalization
Companies near Lixte Biotechnology Holdings Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Lixte Biotechnology Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Lixte Biotechnology Holdings Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, Lixte Biotechnology Holdings Inc's market cap moved from $8.71K to $ 212.85, with a yearly change of -51.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $212.85 | -24.14% |
| 2024 | $280.57 | -23.68% |
| 2023 | $367.65 | -35.59% |
| 2022 | $570.83 | -86.59% |
| 2021 | $4.26K | -51.10% |
| 2020 | $8.71K | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Lixte Biotechnology Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $212.85 USD |
| MoneyControl | $212.85 USD |
| MarketWatch | $212.85 USD |
| marketcap.company | $212.85 USD |
| Reuters | $212.85 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubi… Read more